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Interventional Cardiology
DES Mortality Benefit Found in a Real-World Setting
Shishehbor and colleagues compared all-cause mortality between patients receivingdrug-eluting stents (DES) and bare-metal stents (BMS) while adjusting for untra-
ditional mortality risk factors such as malignancy, depression, anemia, and low socio-
economic status. All-cause mortality was significantly lower in both unadjusted and
adjusted Cox proportional models with DES. These results suggest that DES reduce
the risk of mortality even after adjusting for the untraditional cardiac risk factors that
make some patients more likely to receive a BMS due to perceived inability to comply
with long-term antiplatelet therapy. See page 1041. See figure.
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Atherosclerosis
Polymorphism in Hp Gene Associated With Increased Iron in Plaque
Haptoglobin (Hp) is necessary for removing free hemoglobin (Hb), whose incor-porated iron can act as an inflammatory stimulus. The Hp gene has 2 alleles (1
and2); allele 2 is less efficient at neutralizing iron andhas been associatedwith increased
cardiovascular risk.Moreno and colleagues report that subjects with 2 copies of allele 2
(Hp 2-2) were up to 4 times more likely to have atherosclerotic plaques that stain
positive for iron. These results support the proposition that Hp 2-2 individuals have
impaired clearance of Hb from atherosclerotic plaques. See page 1049. See
figure.
Heart Failure
BBs Show Similar Efficacy to Other Drugs for Primary Prevention of HF
Hypertension doubles the risk of heart failure (HF). Because beta-blockers (BBs)are effective for the treatment of HF, some have postulated that they may more
effectively prevent HF than other antihypertensive agents. Bangalore and colleagues.
performed a meta-analysis of 12 trials with over 100,000 subjects with hypertension.
Compared to placebo, BBs reduced blood pressure (BP) and the risk of HF. With
similar reductions in BP, there was no incremental benefit with BB compared to other
medications. PreventingHF correlates stronglywith reducingBP regardless of the class
of medication used. See page 1062.
Page 1079
Heart Rhythm Disorders
Azimilide Reduces Hospitalizations for Patients With ICDs
Azimilide is an investigational Class III antiarrhythmic medication. This is asecondary end point analysis of the SHIELD trial which randomized patients
with symptomatic ventricular arrhythmias, who also had an implantable cardioverter-
defibrillator (ICD), to either azimilide or placebo. The total number of emergency
room (ER) visits andhospitalizations caused by arrhythmias or other cardiac eventswas
compared. The 75-mg dose of azimilide significantly reduced both ER visits and
hospitalizations by 37%and47%, respectively, with 6 as the number needed to treat to
prevent 1 such visit over 1 year. Azimilide significantly reduces the number of ER visits
and hospitalizations in patients with an ICD and a history of symptomatic ventricular
arrhythmias. See page 1076. See figure.
